key: cord-0866747-aqqiy2t4 authors: Kaplan, Blanka; Farzan, Sherry; Coscia, Gina; Rosenthal, David W.; McInerney, Alissa; Jongco, Artemio M.; Ponda, Punita; Bonagura, Vincent R. title: Allergic reactions to COVID-19 vaccines and addressing vaccine hesitancy: Northwell Health experience date: 2021-10-24 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2021.10.019 sha: 2e95cf24c4da98fc754c05623ef9ee3821642ea6 doc_id: 866747 cord_uid: aqqiy2t4 Background: Allergic and nonallergic adverse reactions have been reported with global coronavirus disease 2019 (COVID-19) vaccination. It was previously hypothesized that polyethylene glycol (PEG) may be responsible for anaphylactic reactions to mRNA COVID-19 vaccines. Objective: To report the workflow established at our institution, types, and frequency of adverse reactions to mRNA COVID-19 vaccines in patients presenting for allergy evaluation. Methods: A COVID-19 vaccines adverse reactions registry was established. We used PEG prick skin testing, followed by PEG challenges in selected cases, to ensure PEG tolerance and encourage completion of COVID-19 vaccination series. Results: A total of 113 patients were included. Most vaccine reactions (86.7%) occurred in women. Anaphylaxis occurred only in women, all of which had a history of allergic disease and two-thirds had asthma. Anaphylaxis rate was 40.6 cases per million. None of the anaphylactic cases developed hypotension, required intubation or hospital admission. Systemic allergic symptoms, not fulfilling anaphylaxis criteria were significantly more common in Pfizer-BioNTech than Moderna vaccinated patients (p=0.02). We observed a higher incidence of dermatologic non-urticarial reactions in men (p=0.004). Among first dose reactors, 86.7% received and tolerated second dose. We observed a high rate of false positive intradermal skin tests and frequent subjective symptoms with oral PEG challenge. Conclusion: Intradermal PEG testing has limited utility in evaluating anaphylaxis to mRNA vaccines. Most severe postvaccination allergic symptoms are not caused by hypersensitivity to PEG. The majority of people with reaction to the initial mRNA vaccine can be safely revaccinated. Patients with anaphylaxis to COVID-19 vaccines benefit from physician-observed vaccination. Results: A total of 113 patients were included. Most vaccine reactions (86.7%) occurred in women. Anaphylaxis occurred only in women, all of which had a history of allergic disease and two-thirds had asthma. Anaphylaxis rate was 40.6 cases per million. None of the anaphylactic cases developed hypotension, required intubation or hospital admission. Systemic allergic symptoms, not fulfilling anaphylaxis criteria were significantly more common in Pfizer-BioNTech than Moderna vaccinated patients (p=0.02). We observed a higher incidence of dermatologic non-urticarial reactions in men (p=0.004). Among first dose reactors, 86.7% received and tolerated second dose. We observed a high rate of false positive intradermal skin tests and frequent subjective symptoms with oral PEG challenge. Conclusion: Intradermal PEG testing has limited utility in evaluating anaphylaxis to mRNA vaccines. Most severe postvaccination allergic symptoms are not caused by hypersensitivity to PEG. The majority of people with reaction to the initial mRNA vaccine can be safely revaccinated. Patients with anaphylaxis to COVID-19 vaccines benefit from physician-observed vaccination. As of October 1, 2021, over 233 million coronavirus disease 2019 (COVID-19) cases and over 4.77 million COVID-19 related deaths have been reported. Highly immunogenic COVID-19 vaccines offer robust protection, 1, 2 and are powerful tools to control the pandemic. Within the first few days of international vaccination efforts, systemic allergic reactions were reported at rates higher than those with other vaccines. [3] [4] [5] Consequently, in December 2020, the Centers for Disease Control and Prevention (CDC) recommended against vaccinating people with severe or immediate allergic reactions after a dose of a COVID-19 mRNA vaccine, or any of its components, and suggested referral to an allergist-immunologist for further evaluation. 6, 7 It has been hypothesized that polyethylene glycol (PEG) may be responsible for anaphylactic reactions to the COVID-19 mRNA vaccines, 8 and initial guidance on risk stratification and management of patients allergic to the mRNA vaccines, was based on PEG testing. 9 While multiple factors contribute to vaccine hesitancy, concern about adverse effects is one of the leading causes of vaccine refusal and delay in vaccination. 10 As allergists, we addressed patients' questions about allergic and other adverse reactions to COVID-19 vaccines to minimize vaccine hesitancy. We evaluated patients with reported reactions, performed testing and challenges where applicable, and provided counseling about risks and benefits of vaccination. Here we report our experience and the types of adverse reactions to COVID-19 vaccines seen for consultation in the Division of Allergy and Immunology at Northwell Health, which employs more than 74,000 people in 23 hospitals and more than 700 outpatient settings. Patients referred to be seen in our office for COVID-19 vaccine reactions from January 2021 through May 2021 were prospectively evaluated. A COVID-19 vaccines adverse reactions registry for people who had adverse reactions and were evaluated in the Division of Allergy and Immunology was established. Demographic data, details of adverse reactions to COVID-19 vaccination and allergy evaluation, previous allergic and relevant medical history, were included in the registry. This study was approved by the Institutional Review Board of the Feinstein Institutes of Medical Research at Northwell Health. Written consent was obtained. With the initiation of the national COVID-19 vaccination program, we established a referral process for vaccine reactions via collaboration with the Northwell Employee Health System, Emergency Departments (ED), vaccination PODs (Point of Dispensing), ambulatory physicians, hospitalists and the Northwell COVID Ambulatory Resource Support (CARES) program ( Figure 1 ). Education was provided by our faculty to Emergency Department (ED), ambulatory and hospital medicine faculty regarding COVID-19 vaccine reactions, management, indications for allergy referrals, and recognition and treatment of anaphylaxis. An online educational module on identifying and treatment of anaphylaxis was developed as an additional resource. Our staff attempted to contact every patient referred. Individuals with a reported vaccine reaction were triaged over the phone by the allergy fellows-in-training and telehealth or in-person visits were scheduled within a week with one of the six faculty attending physicians. People with acute allergic postvaccination symptoms were seen within 24 hours. A thorough history was obtained and recommendations for further evaluation and/or COVID-19 vaccination, based on current knowledge, CDC guidance 11 and communications from AAAAI/ACAAI, 12, 13 were provided. Depending on the type of reaction and history, office visits for skin testing were scheduled. Inoffice oral challenges to PEG (MiraLAX®) were offered in select cases. Management algorithms for different types of COVID-19 vaccine reactions were developed and adapted as our knowledge evolved. A high-risk vaccination clinic was established for patients who had a reaction to the first dose and patients with concerns about allergic reactions to COVID-19 vaccines, who preferred to receive vaccination under an allergist's supervision. Given the wide variety of adverse reactions observed, we devised a system to classify the types of reactions (Table 1) into six different groups, using the most significant presenting symptom(s). This classification scheme was based on the types of reactions observed and intended to risk-stratify patients, streamline management of vaccine reactions and facilitate referrals for allergy evaluation, without delaying the second vaccination for people with mild reactions. Groups 1 and 2 included patients with immediate and delayed nonallergic reactions, respectively. Group 3 included patients with various dermatologic symptoms, except generalized urticaria, which was classified in group 5. Patients with subjective tongue and/or throat swelling, and hoarseness were included in group 4. Although the exact mechanism for each patient is difficult to decipher, these symptoms are very disturbing to patients and necessitated an allergy evaluation to exclude hypersensitivity reactions. Group 5 included patients with allergic symptoms, suggestive of IgE-mediated sensitivity. In order to be assigned to Group 6, the patient was required to meet criteria for anaphylaxis according to the Brighton Collaboration case definitions, 14 the National Institute of Allergy and Infectious Disease (NIAID) and Food Allergy and Anaphylaxis Network criteria for anaphylaxis, 15 or both. The designation of anaphylaxis was confirmed by three of the authors (BK, GC, SF). Skin prick and intradermal testing was performed in patients when there was a concern for an IgE-mediated process after COVID-19 mRNA vaccination. Patients with no suspicion for immediate hypersensitivity reaction were not offered skin testing and were cleared for the next vaccine dose. Testing protocols were adapted from Banerji et al. 9, 16 For patients with negative or inconclusive skin testing to PEG3350, and concern for a risk of reaction to the mRNA vaccine, an in-office oral graded challenge to PEG3350 was offered. Seventeen grams of PEG3350 was diluted in 250mL of water. Two-dose (10%, 90%) or three-dose (1%, 10% and 89%) challenges were performed, with doses administered 30 minutes apart. Patients were observed for 60-90 minutes afterwards for the development of signs or symptoms of an acute allergic reaction. We also used a single-blind placebo-controlled PEG3350 challenges in some patients to minimize false-positive results. Skin testing to COVID-19 vaccines was not performed because the United States Food and Drug Administration required an expanded access investigational new drug (IND) application for COVID-19 vaccine skin testing, challenge and desensitization due to the emergency use authorization (EUA) status of the vaccines. To comply, we requested letters of authorization from the manufacturers which were not granted. Patch testing to PEG was performed in patients with delayed non-urticarial rashes. Summary descriptive statistics were calculated for demographics, vaccine type and reaction classification for mRNA vaccines. Incidence of anaphylaxis was calculated based on employee immunization data within the Northwell Health System. The difference between two independent proportions was utilized to compare the proportion of vaccine reactions in each category between the Pfizer-BioNTech and Moderna vaccine groups, using an "N-1" Chi-squared test as recommended by Campbell (2007) and Richardson (2011) with MedCalc. 17 Since December 2020, 212 individuals were referred for COVID-19 vaccine reactions and 114 were evaluated by the Division of Allergy & Immunology faculty. Among the remaining 98 patients, we were unable to reach eighty-three, ten patients no showed and five cancelled their appointments. Of the 114 evaluated, one patient with anaphylaxis was excluded from our analysis because her symptoms started on day 4 after receiving her first Pfizer-BioNTech Eight patients, all women, had anaphylaxis based on Brighton or NAIAD criteria, or both (Table 2 ). Six cases (75%) of anaphylaxis occurred after the first dose of mRNA vaccines and one each Table 3 ). The anaphylaxis rate didn't differ between two mRNA vaccines. We initially implemented the suggested skin testing algorithm. 9 One patient with anaphylaxis to Pfizer-BioNTech vaccine, had positive prick skin test to PEG (Table 2) . Eighteen patients had methylprednisolone acetate skin testing performed at recommended concentrations and in six of them (33%), the skin test was positive. Three of these six patients (50%) had a subsequent negative PEG challenge and tolerated their second mRNA vaccine (Figure 3 ). Seeing a high rate of false-positive tests to methylprednisolone acetate, we decided to proceed with graded PEG challenges after negative PEG prick skin test for patients with an unconvincing history of PEG allergy ( Table 4 ). Ten of 23 (43.5%) patients developed mild, transient symptoms during the PEG3350 challenge. Symptoms included scratchy throat, tingling, numbness of the tongue and palate, sweet taste in the mouth, feeling of swollen tongue, lips, lump in the throat, throat closure sensation, shortness of breath, skin itching and blotching, lightheadedness, and dizziness. All symptoms were subjective, except skin blotching that occurred only in people with history of chronic and intermittent hives. These symptoms were transient, mostly subjective and were not treated, except in one patient with history of urticaria, who developed pruritus and received fexofenadine 180 mg with resolution of symptoms. In some cases, symptoms experienced by an individual during PEG challenge were similar to those experienced by that patient with vaccination. Patients were reassured, educated, and cleared for their second dose with premedication. PEG patch testing was performed and was negative in three patients with delayed rashes. As per published guidance, 9 patients with mild allergic symptoms to the first COVID-19 mRNA vaccine were pretreated with non-sedating antihistamines (e.g. cetirizine 10-20 mg or fexofenadine 180-360 mg 1 hour prior to vaccination). Asthma and chronic urticaria medications were optimized to control underlying conditions. Patients were instructed to take additional doses of cetirizine or fexofenadine for post-vaccination pruritus and rashes. Patients with delayed rashes were recommended to continue antihistamines for a few days (1-2 days longer than duration of the rash after the 1st dose). Patients with history of subjective feeling of throat and tongue swelling, were premedicated with anti-reflux medications (H2 blockers or proton pump inhibitors). Patients with asthma, who had respiratory symptoms with the first dose, were instructed to take Albuterol HFA 2 puffs prior to their second dose. Among 105 patients who reacted to the first dose of COVID-19 mRNA vaccines, 91 (86.7%) completed their vaccination series without any severe immediate reactions (Figure 3 ). Among six patients with anaphylaxis to the first dose of mRNA vaccine, five received the second dose of the same mRNA vaccine ( Table 2) . Four of these patients tolerated vaccination without any allergic symptoms and one patient developed isolated cough (Patient 4). One patient with history of anaphylaxis to the first dose, had a positive PEG prick skin test and a positive intradermal test to Triamcinolone acetonide (contains Polysorbate 80) and did not complete two-dose vaccination series (Patient 1). Notably, the latter two patients had protracted allergic symptoms for days after the first dose. Despite the extremely low rate of anaphylaxis to COVID-19 vaccines, public concern about adverse effects, including allergic reactions remains high, contributing to vaccine hesitancy. Our experience underscores that the majority of people with allergic symptoms after their initial mRNA vaccine can be safely revaccinated with premedication and hypersensitivity to PEG is not the culprit in most cases of severe allergic symptoms. The rate of anaphylaxis to in our cohort is 40.6 cases per million, while previously reported rates of anaphylaxis to COVID-19 mRNA vaccines vary from 4.5 per million, reported by CDC 18 to 247 cases per million doses administered after the first vaccination, reported at Mass General Brigham. 19 The estimated rate of anaphylaxis to non-COVID-19 vaccines is significantly lower, 1.31 per million vaccine doses 5 . The differences in reported anaphylaxis rates can be explained by the extremely low incidence of anaphylaxis to vaccines, variability in applying anaphylaxis criteria and different populations studied. We believe that misdiagnosis and mistakenly assumed causality leads to overestimation of anaphylaxis rate. For example, a patient who developed shortness of breath two hours after vaccination and required intubation, was referred for evaluation of presumed COVID-19 vaccine anaphylaxis. This patient did not have any associated allergic symptoms and was diagnosed with bilateral pneumonia, asthma and acute on chronic respiratory failure. Respiratory failure alone does not fulfill anaphylaxis criteria, tryptase was not checked and the relationship to vaccination is unclear. Also, causality is uncertain for a patient, who developed anaphylaxis four days after vaccination and was thus excluded from our analysis. The reported rate of anaphylaxis to COVID-19 vaccines has been decreasing as the vaccination rate increases and concerns regarding new vaccines diminish, suggesting that anxiety and panic attacks can present with symptoms mimicking allergic reactions, such as shortness of breath, globus sensation, tachycardia and hypertension, and therefore may contribute to a higher reported rate of allergic reactions to COVID-19 vaccines. In our cohort, anaphylaxis occurred only in women, which is similar to previously reported data. 19, 20 There was no statistically significant difference in the rate of anaphylaxis between the Pfizer-BioNTech and Moderna vaccines, but the rate of systemic allergic symptoms (generalized pruritus, urticaria, angioedema, wheezing), was significantly higher in the former and the rate of delayed nonallergic reactions was significantly higher in the latter. Delayed injection site reactions in Moderna-vaccinated patients accounted for higher rate of delayed nonallergic symptoms after Moderna. This is easily managed with reassurance, anticipatory guidance with clear recommendations about symptomatic treatment ( Table 1 ). The reason for higher rate of systemic allergic symptoms in Pfizer-BioNTech-vaccinated patients in our cohort may be due to different excipients in the mRNA vaccines, but these findings should be confirmed by larger studies. Every patient with anaphylaxis to a COVID-19 vaccine had a history of atopy and twothirds had asthma. Underlying asthma and urticaria may contribute to post-vaccination respiratory and cutaneous symptoms, which highlights the importance of optimizing asthma control and that of other underlying diseases prior to immunization. We want to emphasize that in our cohort no one required intensive care or hospital admission. Interestingly, while most allergic and nonallergic vaccine reactions occurred in women, our data indicate that delayed nonurticarial cutaneous reactions may be higher in men. Further research is needed to uncover the etiology for this observed difference in presentation between genders, but experience from other vaccinations has documented higher rates of adverse reactions, including anaphylaxis, in women. 21, 22 Skin testing to the culprit vaccine and its components is the gold standard in evaluating patients with vaccine allergy. 23 Since the predictive value of COVID-19 vaccine skin testing is unknown, and PEG, which is reported to cause rare cases of IgE-mediated reactions, including anaphylaxis, is the only component of mRNA COVID-vaccines that can be tested at this time, initial risk stratification pathways were based on excipient skin testing to PEG. Skin testing to PEG is not standardized and intradermal PEG skin testing can cause anaphylaxis, 24 therefore PEGcontaining methylprednisolone acetate is recommended for intradermal testing. Although PEG and PEG-containing steroid skin testing has been helpful for evaluating immediate hypersensitivity to PEG-containing medications, 25, 26 its value in predicting tolerance to COVID-19 mRNA vaccines is unknown. False-positive skin test results may interfere with the ability to clear patients for their subsequent vaccine dose and lead to labeling patients with new drug allergies. Therefore, we utilized oral PEG challenges to clear and encourage patients to receive their second vaccine doses. Although only 0.06% of oral PEG is absorbed, this results in 10.2 mg of a 17-gram dose, which is much greater than the amount in mRNA vaccines. 27, 28 We observed that at least half of the patients with positive methylprednisolone acetate tests went on to tolerate oral PEG and their second dose of an mRNA vaccine, indicating low specificity of this intradermal skin test. Furthermore, negative PEG challenges after presumed hypersensitivity reactions to mRNA vaccines, indicate that PEG is an unlikely cause of severe allergic symptoms in people who don't have a history of anaphylaxis to PEG. However, one of our patients who developed anaphylaxis to the first dose of mRNA vaccine and had protracted symptoms, had positive PEG prick skin test, suggesting that PEG can be a rare culprit and PEG prick skin test may be helpful for evaluating anaphylaxis to mRNA vaccines in selected cases. Some patients had mild symptoms during their PEG challenge, which sometimes mimicked their symptoms to the initial vaccine. These patients were carefully observed and reassured, and maintenance medications for patients with suboptimally controlled asthma and urticaria were adjusted. Patients were then cleared for their second vaccine dose with premedication. Patients with subjective feeling of "throat symptoms," were additionally empirically premedicated with anti-reflux medications (H2 blockers and/or proton pump inhibitors). All patients (n=91) who went on to receive their second dose, including those with mild symptoms during PEG challenge, tolerated subsequent vaccination with premedication, suggesting that these symptoms are either not allergic, hypersensitivity to PEG is very mild or that there is another allergen within the vaccine that could be triggering reactions. We established a high-risk vaccination clinic to provide a safe and comfortable setting where patients would receive their second dose under the supervision of an allergist trained to identify and treat allergic reactions. All patients tolerated vaccination, administered as a single dose, with appropriate premedication. The majority of our patients with anaphylaxis to the first COVID-19 vaccine received second dose at the high-risk clinic. None of these patients had a severe reaction to the second vaccination. Tolerance of the second dose after reported anaphylaxis to the first one has been reported by others 20, 29 and suggests a non-IgE-mediated mechanism for most of postvaccination reactions. Other immune mechanisms, including direct mast cell activation by vaccine components and various host factors have been proposed. 30 Based on our experience, we believe that intradermal PEG testing has limited utility. Prick PEG testing may be helpful in people with history of anaphylaxis to mRNA vaccines. The majority of severe allergic symptoms, associated with mRNA vaccines, are not caused by hypersensitivity to PEG. Special attention should be given to patients with anaphylaxis, followed by protracted symptoms. Although successful administration of the second dose of mRNA vaccine via graded dosing protocol after immediate hypersensitivity reaction to the first dose, has been described, 31 our data suggest that with premedication, the full dose of mRNA vaccines can be administered safely and is well tolerated in most patients. Obviously, this approach will not be appropriate for rare patients with history of anaphylaxis to PEG. Emerging data on mRNA COVID-19 vaccine skin testing suggest that it is safe, 32,33 but may cause delayed reactions at the skin test sites that were not predictive of immediate hypersensitivity reactions to the vaccines. 34 Sensitivity and specificity of vaccine skin testing are still unknown. With expanding eligibility criteria for vaccination, we have been consulted in increasing numbers for patients with a history of anaphylaxis to medications and vaccines, multiple drug allergies, mast cell disorders, and other allergic concerns, prior to vaccination. We believe that establishing the referral process, educating the healthcare professionals who see the reactions first-hand, and having an allergist evaluate patients early and thoroughly is essential. Initial Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID Vaccine -United States Risk of anaphylaxis after vaccination in children and adults Center for Disease Control and Prevention. COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions Maintaining Safety with SARS-CoV-2 Vaccines mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach Fear of Adverse Effects and COVID-19 Hesitancy: Recommendations of the Treatment Expectation Expert Group Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States-Appendix B Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network Criteria for anaphylaxis COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach MedCalc Software Ltd. Comparison of proportions calculator First Month of COVID-19 Vaccine Safety Monitoring -United States Acute Allergic Reactions to mRNA COVID-19 Vaccines Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose! Allergy Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs Polyethylene-Glycol Induced Systemic Allergic Reactions (Anaphylaxis) Anaphylaxis following a transvaginal ultrasound Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized The United States Food and Drug Administration The United States Food and Drug Administration First Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines Administration of a Second Dose of the Moderna COVID Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing We would like to acknowledge Tyrone Coyle, William Keefe, Stefani Su, Elizabeth Conroy, and Aaqil Ali for their assistance in data collection. Anaphylaxis rate, cases/million doses administered 70. 5 55.5 72.6 0 71. 6 28.3 This analysis assumes that each reaction is an independent event.